NCT06933329View on ClinicalTrials.gov

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

February 28, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Zelenectide pevedotin (BT8009)

Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.

Trial Locations (7)

11590

RECRUITING

Clinical Research Alliance, Inc, Westbury

22201

RECRUITING

Virginia Cancer Specialists, Arlington

45014

RECRUITING

Oncology Hematology Care Clinical Trials, LLC, Fairfield

75203

RECRUITING

Texas Oncology - DFW, Dallas

78758

RECRUITING

Texas Oncology - Central South, Austin

92150

RECRUITING

Hopital Foch, Suresnes

99508

RECRUITING

Alaska Oncology and Hematology, LLC, Anchorage

All Listed Sponsors
lead

BicycleTx Limited

INDUSTRY

NCT06933329 - Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter